Tissue plasminogen activator (t-PA) intravenous thrombolysis has been approved as the principal recommended strategy for the treatment of acute stroke by US Food and Drug Administration (FDA) (Dirnagl et al., 1999; Donnan et al., 2008) The reports stated intravenous thrombolysis within 6 h after the onset of stroke is the only treatment to reduce the disability of stroke patients (Miller et al., 2012; Wardlaw et al., 2012; Demaerschalk et al., 2016; Furie and Jayaraman 2018). The gene discussed is PLAT; the disease is Stroke.